Publications

Explore publications relevant to our product candidates and technologies

This page contains links to third‑party websites and materials that are not owned, controlled, or maintained by Oculis. These links are provided for informational purposes only and are not incorporated by reference into any of Oculis’s SEC filings. Oculis does not endorse, adopt, or make any representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third‑party content, and has no obligation to update such content. References and links to scientific publications may include data and information relating to product candidates that are investigational and not approved by any regulatory authority for the indications discussed. These materials are intended solely to provide scientific information to healthcare and research professionals and are not intended to promote any product, make efficacy or safety claims, or compare products. The publications may present preliminary findings, which are subject to further validation. Nothing on this page constitutes medical advice; patients should consult a qualified healthcare professional regarding diagnosis and treatment decisions. Any views, opinions, findings, or conclusions expressed in third‑party materials are those of the author(s) and do not necessarily reflect the views of Oculis.

Privosegtor

blue ellipse
March 2023
|
NATURE IN SCIENTIFIC REPORTS

A Phase 1 Randomized Study on The Safety and Pharmacokinetics of OCS-05, a Neuroprotective Disease Modifying Treatment for Acute Optic Neuritis and Multiple Sclerosis

PABLO VILLOSLADA ET AL.
July 2019
|
Neurotherapeutics

Axonal and Myelin Neuroprotection by The Peptoid BN201 in Brain Inflammation

Pablo Villoslada et al.

OCS-01

blue ellipse
December 2022
|
CLINICAL THERAPY

OCS-01 (Novel Topical Dexamethasone Formulation) in Inflammation and Pain Post Cataract Surgery: A Randomized, Double-Masked, Vehicle-Controlled Study

MICHAEL KORENFELD ET AL.
February 2023
|
ACTA OPHTHALMOLOGICA

Topical Treatment of Diabetic Macular Edema Using Dexamethasone Ophthalmic Suspension: A Randomized, Double-Masked, Vehicle-Controlled Study

EINAR STEFANSSON ET AL.
October 2021
|
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE

Topical Dexamethasone-Cyclodextrin Microparticle Eye Drops For Diabetic Macular Edema

Masaki Tanito et al.
August 2015
|
ACTA OPHTHALMOLOGICA

Topical Dexamethasone-Cyclodextrin Nanoparticle Eye Drops for Non-Infectious Uveitic Macular Oedema and Vitritis – A Pilot Study

Shiri Shulman et al.
July 2015
|
ACTA OPHTHALMOLOGICA

Topical Dexamethasone γ-Cyclodextrin Nanoparticle Eye Drops Increase Visual Acuity and Decrease Macular Thickness in Diabetic Macular Oedema

Akihiro Ohira et al.

Licaminlimab

blue ellipse
July 2022
|
CLINICAL OPHTHALMOLOGY

Topical Anti-TNFα Agent Licaminlimab (OCS-02) Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease: A Randomized Phase 2 Study

LEE SHETTLE ET AL.
June 2022
|
TRANSLATIONAL VISION, SCIENCE & TECHNOLOGY

Efficacy and Safety of OCS-02 a novel, potent, topical TNFα antibody in acute anterior uveitis (AAU): a phase 2 study 

THEODORE A. PASQUALI ET AL.

OPTIREACH®

blue ellipse
March 2023
|
THE JOURNAL OF DRUG DELIVERY SCIENCE AND TECH

Topical Dexamethasone Delivery to The Retina: An Aqueous Cyclodextrin-Based Microsuspension

THORSTEINN LOFTSSON AND EINAR STEFANSSON
January 2022
|
EXPERT OPINION IN DRUG DELIVERY

Topical Drug Delivery to The Retina: Obstacles and Routes to Success

THORSTEINN LOFTSSON
June 2021
|
ACTA OPHTHALMOLOGICA

Angiotensin Receptor Blockers in Cyclodextrin Nanoparticle Eye Drops: Ocular Pharmacokinetics and Pharmacologic Effect on Intraocular Pressure

LAURA LORENZO-SOLER ET AL.
May 2021
|
PHARMACEUTICALS

Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits

MARTIN KALLAB ET AL.
March 2021
|
INTERNATIONAL JOURNAL OF PHARMACOLOGY

Topical Drug Delivery to The Posterior Segment of The Eye: Thermodynamic Considerations

SUPPAKAN SRIPETCH AND THORSTEINN LOFTSSON

Our potential to transform patients’ lives through visionary innovation

Visionary Innovation